home / stock / mrus / mrus quote
Last: | $43.06 |
---|---|
Change Percent: | 2.6% |
Open: | $41.61 |
Close: | $41.97 |
High: | $43.07 |
Low: | $41.11 |
Volume: | 157,841 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$43.06 | $41.61 | $41.97 | $43.07 | $41.11 | 157,841 | 04-25-2024 |
$41.97 | $41 | $41.97 | $42.02 | $40.6 | 740,772 | 04-24-2024 |
$40.82 | $40.89 | $40.82 | $41.77 | $40.68 | 572,348 | 04-23-2024 |
$40.45 | $39.93 | $40.45 | $41.5 | $39.93 | 705,458 | 04-22-2024 |
$39.81 | $40.56 | $39.81 | $42.375 | $39.27 | 795,015 | 04-19-2024 |
$40.47 | $41.06 | $40.47 | $41.38 | $39.98 | 243,100 | 04-18-2024 |
$41.05 | $40.58 | $41.05 | $41.58 | $40.01 | 409,867 | 04-17-2024 |
$40.31 | $41.11 | $40.31 | $41.11 | $39.7 | 820,134 | 04-16-2024 |
$41.27 | $42.32 | $41.27 | $42.41 | $40.66 | 270,965 | 04-15-2024 |
$41.85 | $42.58 | $41.85 | $42.7114 | $41.2082 | 310,390 | 04-12-2024 |
$43.09 | $42.25 | $43.09 | $43.19 | $41.98 | 558,810 | 04-11-2024 |
$41.74 | $42.42 | $41.74 | $42.7025 | $41.58 | 436,123 | 04-10-2024 |
$42.85 | $44.06 | $42.85 | $44.37 | $42.73 | 767,096 | 04-09-2024 |
$44.01 | $44.7 | $44.01 | $44.9699 | $43.96 | 454,941 | 04-08-2024 |
$44.7 | $44.09 | $44.7 | $45.2366 | $43.89 | 468,391 | 04-05-2024 |
$44.55 | $46.23 | $44.55 | $46.4206 | $44.48 | 374,538 | 04-04-2024 |
$44.58 | $44.84 | $44.58 | $45.27 | $43.96 | 559,226 | 04-03-2024 |
$45.2 | $44.35 | $45.2 | $45.2 | $43.96 | 313,536 | 04-02-2024 |
$45.04 | $45.45 | $45.04 | $45.6 | $43.78 | 561,743 | 04-01-2024 |
$45.03 | $44.91 | $45.03 | $45.32 | $43.87 | 703,062 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Merus N.V. Company Name:
MRUS Stock Symbol:
NASDAQ Market:
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific anti...
2024-04-03 09:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...